AU2012323781B8 - Antibodies to CD1d - Google Patents

Antibodies to CD1d Download PDF

Info

Publication number
AU2012323781B8
AU2012323781B8 AU2012323781A AU2012323781A AU2012323781B8 AU 2012323781 B8 AU2012323781 B8 AU 2012323781B8 AU 2012323781 A AU2012323781 A AU 2012323781A AU 2012323781 A AU2012323781 A AU 2012323781A AU 2012323781 B8 AU2012323781 B8 AU 2012323781B8
Authority
AU
Australia
Prior art keywords
seq
antibody
human
antigen binding
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012323781A
Other languages
English (en)
Other versions
AU2012323781A8 (en
AU2012323781B2 (en
AU2012323781A1 (en
Inventor
Adam CLARKE
Anthony Gerard Doyle
George Kopsidas
Huseyin Mustafa
Jonathan Kannan Nambiar
Matthew Pollard
Lynn Dorothy Poulton
Andrew James Pow
Dedra Tamvakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904190A external-priority patent/AU2011904190A0/en
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Priority to AU2012323781A priority Critical patent/AU2012323781B8/en
Publication of AU2012323781A1 publication Critical patent/AU2012323781A1/en
Publication of AU2012323781B2 publication Critical patent/AU2012323781B2/en
Application granted granted Critical
Publication of AU2012323781A8 publication Critical patent/AU2012323781A8/en
Publication of AU2012323781B8 publication Critical patent/AU2012323781B8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2012323781A 2011-10-14 2012-10-15 Antibodies to CD1d Ceased AU2012323781B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012323781A AU2012323781B8 (en) 2011-10-14 2012-10-15 Antibodies to CD1d

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161547307P 2011-10-14 2011-10-14
AU2011904190A AU2011904190A0 (en) 2011-10-14 Antibodies to CD1d
US61/547,307 2011-10-14
AU2011904190 2011-10-14
PCT/AU2012/001247 WO2013053021A1 (en) 2011-10-14 2012-10-15 ANTIBODIES TO CD1d
AU2012323781A AU2012323781B8 (en) 2011-10-14 2012-10-15 Antibodies to CD1d

Publications (4)

Publication Number Publication Date
AU2012323781A1 AU2012323781A1 (en) 2014-03-27
AU2012323781B2 AU2012323781B2 (en) 2015-04-23
AU2012323781A8 AU2012323781A8 (en) 2015-05-14
AU2012323781B8 true AU2012323781B8 (en) 2015-05-14

Family

ID=48081279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012323781A Ceased AU2012323781B8 (en) 2011-10-14 2012-10-15 Antibodies to CD1d

Country Status (14)

Country Link
US (1) US20140286957A1 (https=)
EP (1) EP2766042A4 (https=)
JP (1) JP2015502915A (https=)
KR (1) KR20140108520A (https=)
CN (1) CN104144700B (https=)
AU (1) AU2012323781B8 (https=)
BR (1) BR112014008691A2 (https=)
CA (1) CA2850961A1 (https=)
EA (1) EA201400447A1 (https=)
IL (1) IL231975A0 (https=)
MX (1) MX2014004326A (https=)
SG (1) SG11201400521PA (https=)
WO (1) WO2013053021A1 (https=)
ZA (1) ZA201401776B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531787B (zh) * 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
SMT202100564T1 (it) * 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
CA3020555A1 (en) * 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
PL3440105T3 (pl) * 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
EP3595683A1 (en) * 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
US11725052B2 (en) * 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
EP4263612A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC Mesothelin binding molecules and uses thereof
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
CN116217704B (zh) * 2022-10-25 2025-08-15 南京医科大学 一种抑制肝细胞凋亡的表面分子及其应用
CN120548186A (zh) * 2022-12-21 2025-08-26 得克萨斯大学体系董事会 功能增强的表达cd3和itcr的工程化的自然杀伤细胞用于过继免疫疗法
WO2024226794A1 (en) * 2023-04-26 2024-10-31 The Trustees Of Indiana University Composition and methods for treatment of spinal cord injury and traumatic brain injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002923A1 (en) * 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
AU2003234443A1 (en) * 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
US20100035843A1 (en) * 2007-02-12 2010-02-11 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity

Also Published As

Publication number Publication date
CA2850961A1 (en) 2013-04-18
SG11201400521PA (en) 2014-08-28
EP2766042A4 (en) 2015-05-27
CN104144700B (zh) 2016-10-19
BR112014008691A2 (pt) 2017-06-13
ZA201401776B (en) 2016-01-27
AU2012323781A8 (en) 2015-05-14
KR20140108520A (ko) 2014-09-11
AU2012323781B2 (en) 2015-04-23
NZ622050A (en) 2016-07-29
EA201400447A1 (ru) 2014-09-30
WO2013053021A1 (en) 2013-04-18
IL231975A0 (en) 2014-05-28
JP2015502915A (ja) 2015-01-29
MX2014004326A (es) 2014-09-25
EP2766042A1 (en) 2014-08-20
US20140286957A1 (en) 2014-09-25
CN104144700A (zh) 2014-11-12
AU2012323781A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
AU2012323781B8 (en) Antibodies to CD1d
US12421314B2 (en) Binding molecules specific for fcγRIIA and uses thereof
CN102439040B (zh) 抗TNF‑α抗体和其用途
AU2008232409C1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
KR101572171B1 (ko) 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
CN105377892A (zh) 抗cd25抗体及其用途
KR20180089514A (ko) Tnf-알파, il-17a 및 il-17f에 대해 특이성을 갖는 다중특이적 항체 분자
AU2020350715A1 (en) GIPR antibody and fusion protein between same and GLP-1, and pharmaceutical composition and application thereof
AU2014233503A1 (en) Anti-CD25 antibodies and their uses
KR101804988B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
KR20180089521A (ko) Tnf 알파에 결합하는 항체 분자
NZ622050B2 (en) ANTIBODIES TO CD1d
CA3022479C (en) Binding molecules specific for fc.gamma.riia and uses thereof
TW202402789A (zh) 抗-tnfr2抗體及其使用方法
AU2013203712A1 (en) Binding Proteins, Including Antibodies, Antibody Derivatives And Antibody Fragments, That Specifically Bind CD154 And Uses Thereof
HK1187630B (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 15 , PAGE(S) 2298 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME TEVA PHARMACEUTICALS AUSTRALIA PTY LTD., APPLICATION NO. 2012323781, UNDER INID (72) CORRECT THE CO-INVENTOR TO READ POULTON, LYNN DOROTHY

Free format text: IN VOL 28 , NO 12 , PAGE(S) 1650 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TEVA PHARMACEUTICALS AUSTRALIA PTY LTD., APPLICATION NO. 2012323781, UNDER INID (72) CORRECT THE CO-INVENTOR TO READ POULTON, LYNN DOROTHY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired